Guido Kroemer

Nov 7, 2024 | nature.com | Guido Kroemer |Léa Montégut

AbstractThe danger theory of immunity, introduced by Polly Matzinger in 1994, posits that tissue stress, damage or infection has a decisive role in determining immune responses. Since then, a growing body of evidence has supported the idea that the capacity to elicit cognate immune responses (immunogenicity) relies on the combination of antigenicity (the ability to be recognized by T cell receptors or antibodies) and adjuvanticity (additional signals arising owing to tissue damage).

Jun 4, 2024 | inria.hal.science | Liwei Zhao |Institut Gustave Roussy |Zhe Shen |Guido Kroemer

Clinically relevant GABARAP deficiency abrogates bortezomib-induced immunogenic cell death in multiple myeloma Mots clés Immunotherapy danger associated molecular pattern autophagy phagocytosis Domaines Cancer Immunothérapie Hématologie Fichier principal Clinically relevant GABARAP deficiency abrogates bortezomib-induced immunogenic cell death in multiple myeloma.pdf (984.15 Ko) Télécharger le fichier Origine Fichiers éditeurs autorisés sur une archive ouverte...

May 26, 2024 | nature.com | Guido Kroemer

Tumorigenesis is driven by the gain-of-function mutation or overexpression of oncogenes, as well as by the inactivation of oncosuppresssive (tumor suppressor) genes due to their loss-of-function mutation, genomic loss, or epigenetic silencing.

Feb 29, 2024 | nature.com | Enyong Dai |Xin McRae Chen |Xuejun Jiang |Rui Kang |Valerian E. Kagan |Ana J. García-Sáez | +27 more

AbstractFerroptosis, an intricately regulated form of cell death characterized by uncontrolled lipid peroxidation, has garnered substantial interest since this term was first coined in 2012. Recent years have witnessed remarkable progress in elucidating the detailed molecular mechanisms that govern ferroptosis induction and defence, with particular emphasis on the roles of heterogeneity and plasticity.

Jan 23, 2024 | nature.com | Guido Kroemer

AbstractRecently we developed a dendritic cell (DC) genotype-phenotype screening platform that is based on CRISPR/Cas9-mediated gene editing of immortalized DC precursors. Whole genome screening for gain-of-function phenotypes led to the identification of BCL2 as a DC-specific immune checkpoint. Genetic or pharmacological inhibition of BCL2 similarly enhanced the antigen presentation capacity of conventional type-1 dendritic cells (cDC1) and mediated T cell-dependent anticancer immunity.